CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
暂无分享,去创建一个
G. V. D. van der Windt | A. Kater | E. Eldering | S. Tonino | I. A. Derks | S. R. Janssen | Liat Izhak | A. Martens | R. V. van Kampen | H. Adams Iii | I. Derks | S. Janssen | Roel van Kampen
[1] N. Worel,et al. CAR T-cell therapy in diffuse large B-cell lymphoma , 2020, memo - Magazine of European Medical Oncology.
[2] D. Baker,et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity , 2019, Science Immunology.
[3] U. Jäger,et al. CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope , 2019, HemaSphere.
[4] E. Thompson,et al. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. , 2018, Cancer discovery.
[5] D. Porter,et al. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy. , 2018, Blood.
[6] E. M. Cook,et al. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. , 2018, Blood.
[7] Hans Bitter,et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.
[8] Mithat Gonen,et al. Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[9] K. Young,et al. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. , 2018, Blood.
[10] Hao Liu,et al. CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells , 2017, Cancer Immunology Research.
[11] O. Elemento,et al. Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms , 2017, Oncoimmunology.
[12] Deborah A. Bowen,et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. , 2017, Blood.
[13] M. Raffeld,et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. , 2017, Blood.
[14] H. Putter,et al. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation , 2017, Bone Marrow Transplantation.
[15] J. Gribben,et al. Chronic lymphocytic leukaemia , 2017, Nature Reviews Disease Primers.
[16] S. Kent,et al. Cytotoxic CD4 T Cells—Friend or Foe during Viral Infection? , 2017, Front. Immunol..
[17] R. Rosenquist,et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers , 2016, Haematologica.
[18] P. Moore,et al. MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies , 2016, Clinical Cancer Research.
[19] S. Heimfeld,et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.
[20] Daniel Li,et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.
[21] Xu Luo,et al. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane , 2016, Genes & development.
[22] S. Kaech,et al. The multifaceted role of CD4+ T cells in CD8+ T cell memory , 2016, Nature Reviews Immunology.
[23] K. Odunsi,et al. Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses , 2015, Scientific Reports.
[24] David L. Porter,et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.
[25] A. Kater,et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors , 2015, Haematologica.
[26] E. Kimby,et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? , 2014, Blood.
[27] E. Remmerswaal,et al. CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. , 2014, Blood.
[28] C. Fegan,et al. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells , 2013, Haematologica.
[29] Lieping Chen,et al. Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.
[30] J. Gribben,et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. , 2013, Blood.
[31] H. Einsele,et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. , 2012, Blood.
[32] P. Kufer,et al. Blinatumomab: a historical perspective. , 2012, Pharmacology & therapeutics.
[33] Michel Sadelain,et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.
[34] J. Timmer,et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. , 2011, Blood.
[35] N. Schmitz,et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. , 2010, Blood.
[36] R. Blasberg,et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts , 2010, The Journal of experimental medicine.
[37] D. Green,et al. Immunogenic and tolerogenic cell death , 2009, Nature Reviews Immunology.
[38] A. Kater,et al. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. , 2008, Blood.
[39] J. Byrd,et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.
[40] T. Hamblin,et al. Chronic lymphocytic leukaemia , 2008, The Lancet.
[41] C. Borner,et al. Granzyme B-induced cell death exerted by ex vivo CTL: discriminating requirements for cell death and some of its signs , 2008, Cell Death and Differentiation.
[42] I. Goping,et al. Cytotoxic T lymphocytes overcome Bcl-2 inhibition: target cells contribute to their own demise. , 2008, Blood.
[43] N. Hellings,et al. CD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. , 2007, Journal of immunology.
[44] N. Hellings,et al. CD4+CD28null T Cells in Autoimmune Disease: Pathogenic Features and Decreased Susceptibility to Immunoregulation1 , 2007, The Journal of Immunology.
[45] J. Gribben,et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. , 2005, Blood.
[46] J. Gribben,et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. , 2005, The Journal of clinical investigation.
[47] A. Morales,et al. High expression of Bfl‐1 contributes to the apoptosis resistant phenotype in B‐cell chronic lymphocytic leukemia , 2005, International journal of cancer.
[48] E. Remmerswaal,et al. CD40 stimulation of B‐cell chronic lymphocytic leukaemia cells enhances the anti‐apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T‐lymphocyte attack , 2004, British journal of haematology.
[49] E. Remmerswaal,et al. Emergence of a CD4+CD28− Granzyme B+, Cytomegalovirus-Specific T Cell Subset after Recovery of Primary Cytomegalovirus Infection , 2004, The Journal of Immunology.
[50] S. Lens,et al. Apoptosis via the B cell antigen receptor requires Bax translocation and involves mitochondrial depolarization, cytochrome C release, and caspase‐9 activation , 2004, European journal of immunology.
[51] M. V. van Oers,et al. Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia. , 2003, Blood.
[52] T. McDonnell,et al. Characterization of 4 mantle cell lymphoma cell lines. , 2003, Archives of pathology & laboratory medicine.
[53] Yong J. Lee,et al. Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis , 2003, The Journal of cell biology.
[54] S. Lederman,et al. CD20-induced B cell death can bypass mitochondria and caspase activation , 2002, Leukemia.
[55] J. Roliński,et al. T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia--the three-color flow cytometry analysis. , 2002, Leukemia research.
[56] S. Korsmeyer,et al. Granzyme B can cause mitochondrial depolarization and cell death in the absence of BID, BAX, and BAK , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[57] D. Green,et al. Granzyme B Short-Circuits the Need for Caspase 8 Activity during Granule-Mediated Cytotoxic T-Lymphocyte Killing by Directly Cleaving Bid , 2000, Molecular and Cellular Biology.
[58] Michael Loran Dustin,et al. Costimulation: Building an Immunological Synapse , 1999, Science.
[59] D. Green,et al. Granzyme B Mimics Apical Caspases , 1998, The Journal of Biological Chemistry.
[60] S. Yonehara,et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. , 1996, Journal of immunology.
[61] E. Kimby,et al. T lymphocyte subpopulations in chronic lymphocytic leukemia of B cell type in relation to immunoglobulin isotype(s) on the leukemic clone and to clinical features , 1987, European journal of haematology.
[62] R. Larson,et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.
[63] N. Schmitz,et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia : long-term clinical and MRD results of the German CLL Study Group CLL 3 X trial , 2010 .